Dumont & Blake Investment Advisors LLC Has $1.16 Million Stock Holdings in DaVita Inc. (NYSE:DVA)

Dumont & Blake Investment Advisors LLC reduced its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 50.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,056 shares of the company's stock after selling 7,094 shares during the quarter. Dumont & Blake Investment Advisors LLC's holdings in DaVita were worth $1,157,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in DVA. Gateway Investment Advisers LLC acquired a new stake in DaVita in the 1st quarter valued at approximately $218,000. Fox Hill Wealth Management increased its position in shares of DaVita by 138.4% during the 1st quarter. Fox Hill Wealth Management now owns 15,734 shares of the company's stock valued at $2,172,000 after purchasing an additional 9,135 shares during the period. Panoramic Investment Advisors LLC acquired a new position in shares of DaVita during the 1st quarter valued at $203,000. Sumitomo Mitsui Trust Holdings Inc. increased its position in shares of DaVita by 1.6% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 134,823 shares of the company's stock valued at $18,612,000 after purchasing an additional 2,129 shares during the period. Finally, Sivia Capital Partners LLC acquired a new position in shares of DaVita during the 1st quarter valued at $220,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at DaVita

In other news, CEO Javier Rodriguez sold 50,000 shares of DaVita stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $165.05, for a total value of $8,252,500.00. Following the transaction, the chief executive officer now directly owns 837,835 shares in the company, valued at approximately $138,284,666.75. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CEO Javier Rodriguez sold 50,000 shares of DaVita stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $165.05, for a total value of $8,252,500.00. Following the transaction, the chief executive officer now directly owns 837,835 shares in the company, valued at approximately $138,284,666.75. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Joel Ackerman sold 64,029 shares of DaVita stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total value of $9,928,336.74. Following the completion of the transaction, the chief financial officer now owns 111,481 shares in the company, valued at $17,286,243.86. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 173,482 shares of company stock worth $27,387,069 over the last three months. Corporate insiders own 2.00% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Truist Financial lifted their price target on DaVita from $165.00 to $175.00 and gave the company a "hold" rating in a research report on Monday, October 7th. TD Cowen raised their price objective on DaVita from $139.00 to $150.00 and gave the stock a "hold" rating in a research note on Wednesday, July 24th. UBS Group raised their price objective on DaVita from $169.00 to $175.00 and gave the stock a "buy" rating in a research note on Thursday, August 8th. Finally, Bank of America raised their price objective on DaVita from $139.00 to $145.00 and gave the stock an "underperform" rating in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, DaVita has a consensus rating of "Hold" and a consensus target price of $159.00.

DaVita Stock Down 2.7 %

Shares of DaVita stock traded down $4.39 during midday trading on Friday, hitting $156.99. The company's stock had a trading volume of 841,780 shares, compared to its average volume of 802,997. The firm has a market capitalization of $13.77 billion, a P/E ratio of 17.84, a PEG ratio of 0.93 and a beta of 0.87. The stock has a 50-day simple moving average of $157.95 and a 200-day simple moving average of $145.34. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94. DaVita Inc. has a 1-year low of $75.47 and a 1-year high of $168.50.

DaVita (NYSE:DVA - Get Free Report) last issued its earnings results on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.47 by $0.12. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The business had revenue of $3.19 billion during the quarter, compared to analysts' expectations of $3.15 billion. During the same quarter last year, the firm posted $2.08 earnings per share. DaVita's revenue was up 6.2% compared to the same quarter last year. As a group, sell-side analysts expect that DaVita Inc. will post 9.99 earnings per share for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.